LeiterLA,BainSC,BhattDLetal.The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.Diabetes Obes Metab.2020;22(9):1690-5
The decision to stop coverage was a difficult, but a fiscally necessary one DAS has worked tirelessly to maintain a generous, competitive benefits plan for all 106,000 state employees and their dependents. DAS is offering health coaching, nutrition and incentive programs and online classes for weight loss, instead, Benton continued
If possible, keep these items in their original packaging to minimize confusion
What Clinicians Should Realistically Take Away The growing conversation around GLP-1 therapies and Parkinsons disease reflects both promise and uncertainty
Hims Faces Greater Competition, Mixed Analyst Support Overall, it will likely take several quarters to determine whether Amazons entry into this market significantly harms Hims's growth
The supplement industry is plagued by inconsistencies and underdosed compounds
